Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT2 | P31751 | 4/20 | 0.53 |
| ▸ | AKT1 | P31749 | 1/20 | 0.53 |
| ▸ | ILK | Q13418 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.35 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | FYN | P06241 | 2/20 | 0.34 |
| ▸ | CLK2 | P49760 | 2/20 | 0.34 |
| ▸ | HIPK1 | Q86Z02 | 2/20 | 0.34 |
| ▸ | HIPK2 | Q9H2X6 | 2/20 | 0.34 |
| ▸ | HIPK3 | Q9H422 | 2/20 | 0.34 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.34 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
| ▸ | CLK1 | P49759 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16617063 | 0.73 | ROCK2 (0.39) | AKT2AKT1ILKROCK2 | |
| SCHEMBL3150004 | 0.72 | AKT2 (0.47) | AKT2AKT1ILKROCK2PIM1 | |
| Benzene SCHEMBL28198087 | 0.70 | AKT2 (1.00) | AKT2AKT1ILKROCK2CHEK1 | |
| SCHEMBL82741 | 0.70 | AKT2 (1.00) | AKT2AKT1ILKROCK2CHEK1 | |
| SCHEMBL722168 | 0.69 | ATM (0.54) | PIM1 | |
| SCHEMBL183516 | 0.69 | ALDH1A1 (0.35) | — | |
| SCHEMBL41140 | 0.69 | ALDH1A1 (0.42) | — | |
| SCHEMBL38202 | 0.69 | ALDH1A1 (0.42) | — | |
| SCHEMBL22462982 | 0.69 | NPBWR1 (0.45) | AKT2AKT1ROCK2ABL1PDK2 | |
| SCHEMBL16872766 | 0.69 | AKT2 (0.95) | AKT2AKT1ILKROCK2CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 423 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2780322-B1 | METHODS AND COMPOSITIONS ASSOCIATED WITH THE GRANULOCYTE COLONY-STIMULATING FACTOR RECEPTOR | LIGAND PHARM INC (US) | 2018-05-16 | — | — | EP | claimed |
| EP-1891067-B1 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARM INC (US) | 2016-01-13 | — | — | EP | claimed |
| WO-2012138648-A1 | COMPOSITIONS AND METHODS FOR MODULATING LPA RECEPTORS | IRM LLC (BM) | 2012-10-11 | — | — | WO | claimed |
| EP-2049502-B1 | 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-01-04 | — | — | EP | claimed |
| US-20090258882-A1 | 2,4-Substituted Quinazolines as Lipid Kinase Inhibitors | NOVARTIS AG | 2009-10-15 | — | — | US | claimed |
| CN-101490016-A | 2,4-substituted quinazolines as lipid kinase inhibitors | NOVARTIS AG (CH) | 2009-07-22 | — | — | CN | claimed |
| EP-2049502-A1 | 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS | Novartis AG (CH) | 2009-04-22 | — | — | EP | claimed |
| EP-1973886-A2 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2008-10-01 | — | — | EP | claimed |
| WO-2008012326-A1 | 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-01-31 | — | — | WO | claimed |
| WO-2007079163-A2 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-12 | — | — | WO | claimed |
| CN-118146635-A | Coating composition with polysiloxane modified carbon nanoparticles | NGNT材料科学公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-110946865-B | Methods for treating huntington's disease | PTC医疗公司 | 2024-01-26 | — | — | CN | disclosed |
| US-11773110-B2 | Heterocycle amines and uses thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230201161-A1 | Combination comprising HDAC inhibitor, LAG-3 inhibitor and a PD-1 inhibitor or PD-L1 inhibitor for cancer treatment | 4SC AG (DE) | 2023-06-29 | — | — | US | disclosed |
| US-20230201201-A1 | COMPOSITION FOR USE IN THE TREATMENT OF APOL1-ASSOCIATED DISEASE | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2023-06-29 | — | — | US | disclosed |
| US-20040180893-A1 | enzymatically or synthetically prepared alpha-hydroxyglycinamide inhibit the replication of HIV in human serum | TRIPEP AB (SE) | 2004-09-16 | — | — | US | disclosed |
| WO-2004073703-A1 | GLYCINAMIDE DERIVATIVE FOR INHIBITING HIV REPLICATION | TRIPEP AB (SE) | 2004-09-02 | — | — | WO | disclosed |
| CN-1517341-A | Pyrazolylalkyne | 拜尔化学品股份公司 | 2004-08-04 | — | — | CN | disclosed |
| US-20040106600-A1 | N-substituted piperidine derivatives as serotonin receptor agents | ACADIA PHARMACEUTICALS, INC. | 2004-06-03 | — | — | US | disclosed |
| WO-2004000808-A2 | N-SUBSTITUTED PIPERIDINE DERIVATIVES AS SEROTONIN RECEPTOR AGENTS | ACADIA PHARMACEUTICALS INC. (US) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230201201-A1 | COMPOSITION FOR USE IN THE TREATMENT OF APOL1-ASSOCIATED DISEASE | APOL1, APOB, LIPA | AKT2 3982/4885AKT1 4514/4885ILK 2724/4885 |
| US-20040106600-A1 | N-substituted piperidine derivatives as serotonin receptor agents | HTR1A, HTR5A, HTR1B | AKT2 1237/4885AKT1 1064/4885ILK 4877/4885 |
| US-11773110-B2 | Heterocycle amines and uses thereof | HNMT, NQO1, ACHE | AKT2 2015/4885AKT1 1503/4885ILK 2361/4885 |
| US-20090258882-A1 | 2,4-Substituted Quinazolines as Lipid Kinase Inhibitors | PDPK1, PI4KA, PIK3CA | AKT2 64/4885AKT1 85/4885ILK 2080/4885 |
| US-20040180893-A1 | enzymatically or synthetically prepared alpha-hydroxyglycinamide inhibit the replication of HIV in human serum | ENGASE, GALE, OGA | AKT2 3324/4885AKT1 3301/4885ILK 3267/4885 |
| US-20230201161-A1 | Combination comprising HDAC inhibitor, LAG-3 inhibitor and a PD-1 inhibitor or PD-L1 inhibitor for cancer treatment | HDAC1, HDAC3, HDAC11 | AKT2 2257/4885AKT1 1965/4885ILK 1468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.